Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by Bradwaiton Feb 10, 2021 7:40am

144 Views

Post# 32522407

Media Hype for Ifenprodil

I believe we are in for huge media hype for Ifenprodil with successful endpoints from Phase 2b.

The COVID-19 pandemic is the biggest health crisis of our lifetime so to have a drug that may prevent lung damage and repair lung damage is huge to say the least.

Keep in mind that we have this for all respiratory illnesses.

This can be a turning point company maker for AGN. Plus you have to love the outlook for our new DMT drug for stroke patients.

We seriously could have 2 blockbusters on our hands and our current market cap is very tiny considering this so the room for growth and share price appreciation is enormous.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features